secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001808805-26-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M
--------------------------------------------------------------

- Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.
- Cash, equivalents, and investments total $143.4M as of March 31, 2026.
- Launched Iterative Mapping Early Access Program; Baylor College of Medicine first customer for Tau proteoform assay in NIH-funded cancer study.
- Appointed Amber Faust as VP of Global Sales, a commercial leader from Olink and SomaLogic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/0001808805-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000015/naut-20260428.htm
  HTML page:      https://secwatch.observer/filing/0001808805-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer